Objectives: Butyrylcholinesterase (BChE) is an alpha-glycoprotein synthesized in the liver. Its serum levels are reportedly correlated with disease activity in patients with cancer. The aim of this study was to estimate the potential prognostic significance of preoperative serum BChE levels in patients with upper urinary tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). Methods: Of the 220 patients with UTUC who underwent RNU between 1995 and 2016 at Hirosaki University Hospital, 149 patients with available laboratory data were included for analysis. Covariates included age, sex, preoperative laboratory data, clinical T and N grades, tumor grade, tumor location and preoperative chemotherapy. Univariate and multivariate analyses were performed to identify clinical factors associated with overall survival (OS) and disease-free survival (DFS). Univariate analysis was performed using the Kaplan-Meier and log-rank methods, and the multivariate analysis was performed using a Cox proportional hazard model. Results: The median BChE level was 276 U/l and the optimal cut-off point for the serum BChE level was determined to be 218 IU/ml. The 5-year OS and DFS rates were 81.0% and 73.7%, respectively. The 5-year OS and DFS rates were significantly greater in the BChE ≥ 218 than <218 U/l groups (86.6% vs. 53.7%, P < 0.001 and 76.4% vs. 58.3%, P = 0.049, respectively). In multivariate analysis, BChE levels were most significantly associated with OS, whereas BChE level and tumor grade were significantly associated with DFS. Conclusions: This study validated preoperative serum BChE levels as an independent prognostic factor for UTUC after RNU.
Introduction
Upper urinary tract urothelial carcinoma (UTUC) is a relatively rare, accounting for~5-10% of all urothelial carcinomas worldwide (1) . Radical nephroureterectomy (RNU) with bladder cuff resection is the gold standard for the treatment of nonmetastatic UTUC (2); however, early tumor recurrence occurs in up to 30% of patients, and 80% eventually succumb to the disease (3) . Most studies examining UTUC prognosis have been retrospective evaluations of postoperative prognostic parameters that are available following RNU [e.g., pathological T stage, lymphovascular invasion, tumor location and concomitant carcinoma in situ (4)] and may have reported on a relationship between survival and a number of pretreatment clinical features, including neutrophil to lymphocyte ratio (NLR) (5), fibrinogen (6) and several molecular markers (7) . However, the clinical courses of patients with UTUC vary and thus, are difficult to predict preoperatively.
Cholinesterases are enzymes that hydrolyze the neurotransmitter acetylcholine. Butyrylcholinesterase (BChE) is a nonspecific cholinesterase, and is able to hydrolyze acetylcholine, as well as other esters. Serum BChE is an alpha-glycoprotein mainly found in the central and peripheral nervous system and the liver, with lower levels in most other tissues. Recently, BChE levels were reported to be correlated with disease activity and suggested to be an effective predictor of cancer survival (8, 9) . Serum BCE was evaluated as a potential biomarker in patients with neuroblastoma and oral squamous cell carcinoma (10,11). Battisti et al. reported that BChE activities decreased in patients with prostate cancer (12) . In fact, the results of our previous study showed that decreased levels of pretreatment serum BChE is a useful parameter to predict the oncological outcomes of muscle-invasive bladder cancer (MIBC), prostate cancer (Pca) and renal cell carcinoma (RCC) (13) (14) (15) . However, the value of serum BChE levels to predict the oncological outcomes of patients with UTUC is unknown. Therefore, the aim of this study was to evaluate the significance of pretreatment serum BChE levels to predict UTUC outcomes following RNU.
Methods

Study population
In this study, clinical and pathological records of patients with UTUC who underwent RNU with or without preoperative neoadjuvant chemotherapy (NAC) at Hirosaki University Hospital (Hirosaki, Japan) between February 1995 and April 2016 were retrospectively reviewed. Eligible patients had confirmed histologically as T1-T4 urothelial carcinoma of the upper urinary tract without distant metastasis. Patient features collected for analysis included age, sex, preoperative laboratory data (hemoglobin [Hb] , NLR, BChE, lactate dehydrogenase [LDH], Creactive protein [CRP]), as well as clinical T (cT) and N (cN) tumor grades, tumor location and use of NAC. The diagnosis of UTUC was confirmed by ureteroscopy (with or without biopsy), brush cytology, urine cytology and computed tomography (CT). Information on patients and tumor characteristics was obtained from medical charts.
The survey protocol and informed consent form were reviewed and approved by the Institution Review Committee of Hirosaki University.
Treatment
The patients were treated with RNU with removal of the bladder cuff either openly or laparoscopically with no lymph node dissection. If an invasive cancer was located at the end of the ureter, partial cystectomy was also performed. A total of 30 patients received neoadjuvant gemcitabine and carboplatin (GCarbo), and six received neoadjuvant gemcitabine and cisplatin (GC). In the GCarbo group, patients received two cycles of 800 mg/m 2 GCarbo at an area under the curve of 4. In the GC group, patients received two cycles of gemcitabine at 800 mg/m 2 and cisplatin at 70 mg/m 2 . The NAC regimens were based on estimated glomerular filtration rate (16) . All UTUC patients with cT3 or T4 status at our institution received neoadjuvant GCarbo or GC therapy from 2013 onward. Not all patients received adjuvant chemotherapy.
Patient evaluation
The following baseline information was obtained for complete history and physical examination findings: performance status according to the Eastern Cooperative Oncology Group classification criteria, abdominal and pelvic CT, and chest X-ray. The NLR and Hb (normal range, 13.5-17.0 g/dl), serum BChE (normal range, 168-470 U/l), LDH (normal range, 119-229 U/l), and CRP (normal range, 0-0.3 mg/dl) levels were measured 1 week before RNU. The low levels with covariate parameters (i.e. Hb, NLR, BChE, LDH and CRP) were defined according to the area under the receiver operating characteristic (ROC) curve. The cut-off point was defined as the minimal value for (1 − sensitivity) 2 + (1 − specificity) 2 (17) .
No patient showed signs of active infection or inflammation at the time of surgery. Specimens obtained during RNU were extensively tested to reaffirm the presence of UTUC. Tumor staging was based on the American Joint Committee on Cancer Staging Manual (18).
Follow-up schedule
Each patient was evaluated every 3 months using ultrasonography (to check for hydronephrosis), urine cytology, and kidney and liver function tests. CT images between the chest and pelvis were acquired every 6 months for 5 years, then every year afterward.
Endpoints and statistical analysis
The endpoints of this study were overall survival (OS) and diseasefree survival (DFS). Clinical data were analyzed using SPSS 24 statistical software (IBM Corp., Armonk, NY, USA). Survival following RNU was analyzed using the Kaplan-Meier method. Survival along with subgroup classification was analyzed using the log-rank test. DFS was defined as the time from RNU to recurrence of local or regional disease/metastasis or death. Univariate analyses were performed using the Kaplan-Meier and log-rank methods, and multivariate analysis was performed with a Cox proportional hazard model. All P values were 2-sided, and the significance level was set at <0.05.
Results
Patient characteristics
Of a total of 220 patients with UTUC who underwent RNU between February 1995 and April 2016, 149 (67.7%) were enrolled in this study after excluding 71 (32.3%) because of missing covariate data. The pretreatment characteristics of the patients are shown in Table 1 .
The median Hb level and NLR were 12.8 g/dl (interquartile rate [IQR], 11.4-14.6) and 2.22 (IQR, 1.62-3.26), respectively. The median serum levels of BChE, LDH and CRP were 276 U/l (IQR, 242-321), 201 U/l (IQR, 178-224) and 0.1 mg/dl (IQR, 0.1-0.29), respectively. The serum BChE level was estimated to be 218 U/l by using ROC analysis, which had a sensitivity of 87.4% and a specificity of 59.1%. Therefore, 218 U/ml was adopted as the optimal cutoff point for serum BChE levels. Likewise, the cut-off points for NLR, LDH level, CRP level were determined to be 1.979, 190 U/l and 0.1 mg/dl, respectively. Demographic data of the patients were classified into two groups according to their serum BChE levels ( Table 2) .
Oncological outcomes
The postoperative median follow-up period was 40.4 months (IQR, 21.9-55.9). The 5-year overall OS and DFS rates were 81.0% (95% confidence interval (CI), 82.5-97.7), and 73.7% (95% CI, 60.9-117.7), respectively (Fig. 1) .
In regard to serum BChE levels, the 5-year OS rates were 86.6% in the BChE ≥ 218 U/l group (95% CI, 87.8-103.0) and 53.7% in the BChE < 218 U/l group (95% CI, 42.6-76.0) (P < 0.001; Fig. 2A ). Along with tumor grade, the 5-year OS rates were 84.3% for the patients with Grade 2 disease (95% CI, 75.4-87.3) and 79.1% for the patients with Grade 3 disease (95% CI, 74.5-94.8) (P = 0.029; Fig. 2B ). According to tumor location, the 5-year OS rates were 91.6% for patients with renal pelvis tumor (95% CI, 67.6-78.5), 79.7% for those with ureter tumor (95% CI, 78.2-98.8), and 26.8% for those with both renal pelvic and ureter tumors (95% CI, 26.0-63.3) (pelvis vs. both P = 0.01, ureter vs. both P = 0.02; Fig. 2C ). On multivariate analysis, serum BChE was most significantly associated with OS (Table 3) . In regard to serum BChE level, the 5-year DFS rates were 76.4% in the BChE ≥ 218 U/l group (95% CI, 66.9-79.6) and 58.3% in the BChE < 218 U/l group (95% CI, 42.1-79.4) (P = 0.049; Fig. 3A) . Along with tumor grade, the 5-year DFS rates were 97.4% for the patients with Grade 2 disease (95% CI, 82.5-88.4) and 62.1% for the patients with Grade 3 disease (95% CI, 55.8-73.4) (P < 0.001; Fig. 3B ). According to tumor location, the 5-year DFS rates were 79.2% for patients with renal pelvis tumor (95% CI, 61.7-75.1), 73.4% for those with ureter tumor (95% CI, 62.9-81.2), and 42.9% for those with both renal pelvic and ureter tumors (95% CI, 15.7-67.1) (pelvis vs. both P = 0.01, ureter vs. both P = 0.045; Fig. 3C ). On multivariate analysis, tumor grade and serum BChE level were significantly associated with DFS (Table 3) .
The levels of Hb, NLR, serum LDH and CRP showed no correlation with OS and DFS. The clinical T status, lymph node involvement and RNU with or without NAC also showed no correlation with OS and DFS.
Discussion
The present study demonstrated a direct correlation between serum BChE levels and disease progression in patients with UTUC. To our knowledge, this is the first study of a direct correlation between serum BChE level and UTUC progression following RNU. Choline esterase (ChE) decomposes acetylcholine (ACh) into choline (Ch) and acetic acid. There were two types of ChE: acetylcholinesterase (AChE) and BChE (19) . AChE has the fastest reaction rate among enzymes present in the human body (19) . It exists in synapses, mainly between muscle cells and nerve cells, where it is involved in motor nerve function (19) . Moreover, BChE abundantly exists in the hippocampus and liver, where it decomposes Ach, similar to AChE (19) . BChE is synthesized in the liver, and hepatocellular impairment will result in a decrease in enzyme activity. BChE is composed in the liver, thus hepatocellular impairment results in decreased enzymatic activity (19) . In fact, BChE levels are often decreased in response to acute and chronic liver damage, cirrhosis The 5-year OS rates were 84.3% for the patients with Grade 2 disease and 79.1% for the patients with Grade 3 disease (P = 0.029). (C) Kaplan-Meier estimate of OS according to tumor location. The 5-year OS rates were 91.6% for patients with renal pelvis tumor, 79.7% for those with ureter tumor, and 26.8% for those with both renal pelvic and ureter tumors (pelvis vs. both P = 0.01, ureter vs. both P = 0.02).
and liver metastasis, as well as protein energy malnutrition, stress, inflammation and other clinical manifestations (20) .
Inflammatory responses play a decisive role at various stages of tumorgenesis, including invasion, progression and malignant conversion (21) . Progressive cancer is generally characterized by mild to moderate systemic inflammation, which is a factor of poor prognosis in various malignancies (22) . Serum BChE activity was suggested to be a useful marker of systemic inflammation of some clinical conditions (23) . Also, serum BChE levels were found to be decreased in advanced cancer patients with or without hepatic involvement, despite normal results for other parameters of liver function (24) . In addition, serum BChE level has been shown to be a prognostic factor together with the albumin level and Karnofsky index in terminal cancer patients with peritoneal carcinomatosis (25) .
Several studies have reported correlations between decreased BChE levels and various cancers. In a previous retrospective analysis of patients with clear-cell renal carcinoma, invasive bladder cancer and prostate cancer, we have reported that the preoperative BChE level was an independent prognostic factor for overall survival (13) (14) (15) . Moreover, a recent prospective study conducted by Pavo et al. of 555 patients with a primary diagnosis of cancer without prior treatment found that serum BChE and albumin levels were predictors of long-term and all-cause mortality independent from malignant hepatic involvement in a treatment-naïve cohort of cancer patients (9) . In this report, they concluded that decreased serum BChE and albumin levels were associated with increased all-cause mortality in treatmentnaïve cancer patients (9) . Further, they concluded that a robust association between cancer mortality and decreased serum BChE levels reflected progressive systemic inflammation and metabolic derangement with subclinical involvement of the liver (9) .
A possible mechanism underlying decreased BChE activity in cancer is secondary cachexia accompanied by malignancy (26) . Recently, it has been reported that BChE and ghrelin were inversely correlated in animal models (27) . Ghrelin is composed of 28 amino acids and acts as a ligand of the growth hormone secretagogue receptor. Ghrelin is often termed the 'hunger hormone' and this hormone has the potential to increase appetite, fat and muscle mass. Wolf et al. suggested that ghrelin levels were significantly higher in the cancer cachexia patients compared with noncachexia patients (28). In addition, serum ghrelin levels were negatively correlated with body mass index in humans (29) . From the above, it is expected that serum BChE levels are low in the cancer-related cachexia patients. In fact, Inamoto et al. reported that smaller body mass index remained an independent predictor for worse cancer specific survival with UTUC (30) . Several studies reported that pathological T stage, lymphovascular invasion and concomitant carcinoma in situ were useful postoperative variables to predict oncological outcomes in patients with UTUC who underwent RNU (3,4,7) . The clinical course of UTUC patients varies and can be difficult to predict preoperatively. BChE is a nonspecific serum biomarker. Therefore, decreased serum BChE levels may be the result of inflammation or physical stress. However, in UTUC, a particularly low serum BChE level suggests a systemic disorder, such as malnutrition. In addition, BChE levels seem to be related to UTUC activity and nutritional status.
There were several limitations to the present study that should be addressed. First, this was retrospective study with a relatively small number of patients. Second, although the enrolled patients were divided into two groups in this study according to ROC analysis, our findings were limited, because the group with BChE < 218 U/l was too small compared with the others.
In conclusions, serum BChE levels may have potential to predict prognosis and disease progression in patients with UTUC, although further research is needed to verify these results.
